Sterile ophthalmic manufacturing is facing growing demand as more preservative-free therapies move through development, while manufacturers also contend with increasingly stringent expectations around contamination control, inspection, and quality. Blow-fill-seal (BFS) technology offers a closed, highly automated approach that can reduce contamination risks while producing billions of unit doses at scale.
In this episode of Off Script, we spoke with Jody Chastain, CEO of The Ritedose Corporation, about the role of BFS in the future of sterile ophthalmic manufacturing. Chastain discussed how automation is improving manufacturing speed and container integrity, why packaging decisions are increasingly being made earlier in development, and how manufacturers are adapting to evolving FDA expectations and Annex 1 principles. He also explored manufacturing redundancy, AI-enabled quality operations, automated inspection, and the future of BFS technology.
Podden och tillhörande omslagsbild på den här sidan tillhör
Pharma Manufacturing. Innehållet i podden är skapat av Pharma Manufacturing och inte av,
eller tillsammans med, Poddtoppen.
